Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence

Eli Lilly (LLY) is more than just a weight-loss drug company, as evidenced by its latest third-quarter earnings update. The company's impressive growth was driven by its weight loss medicine, Zepbound, which saw a 49% increase in revenue to $5.4 billion year-over-year, and Mounjaro, an anti-obesity drug, which increased sales by 65% to $10.7 billion. Together, these two medications accounted for 66% of Eli Lilly's total revenue, which itself rose 39% year-over-year to $24.4 billion.

However, Eli Lilly's success extends beyond its GLP-1 portfolio. The company boasts several promising products in various therapeutic areas that could become blockbuster treatments in the future. For instance, Kisunla, a potential Alzheimer's disease treatment, has recently received a label expansion for first-line treatment of certain patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Ebglyss, a medication for atopic dermatitis (eczema), received a label expansion for maintenance dosing every eight weeks, making it more convenient for patients. Omvoh, which treats ulcerative colitis, also received a label expansion. Lastly, Kisunla, an Alzheimer's disease drug, has entered a market with few treatment options and a large addressable opportunity due to the world's aging population.

These additional medications, alongside Eli Lilly's deep pipeline of promising drugs like Inluriyo, an investigational cancer treatment, and remternetug, a potential Alzheimer's disease drug, demonstrate the company's diversification beyond its core weight-loss therapy. As Eli Lilly continues to expand its portfolio and face increased competition in its GLP-1-focused area, it is well-positioned for continued growth and success in the medium term.